The EAZ171 trial aimed to prospectively validate germline predictors of taxane-induced peripheral neuropathy and compare rates of neuropathy and dose reductions in Black women receiving paclitaxel or docetaxel for early-stage breast cancer. Results were presented by Schneider et al at the 2024 ASCO Annual Meeting and were published simultaneously in the Journal of Clinical Oncology.
